Tremfya® shows promise in Phase III psoriatic arthritis study
Tremfya inhibited radiographic progression and provided durable improvements in symptoms of axial involvement in psoriatic arthritis patients.
List view / Grid view
News
AstraZeneca transfers rights for Eklira and Duaklir to Covis Pharma
AstraZeneca will transfer its global rights to their two chronic obstructive pulmonary disease drugs Eklira and Duaklir to Covis Pharma.
Drug repurposing pilot to support not-for-profit organisations and academia
The European Medicines Agency (EMA)'s pilot project will support not-for-profit organisations and academia in gathering evidence for the use of a drug in a new indication.
Aramchol™ reduces fibrosis progression in 24 weeks
Aramchol reduced liver fibrosis progression in 15 out of 16 patients and did not worsen non-alcoholic steatohepatitis in almost half of patients.
FDA authorises Comirnaty® for emergency use in five to 11 year olds
The US Food and Drug Administration has authorised the emergency use of COVID-19 vaccine Comirnaty in children aged five to 11 years.
BARDS: a potential in-process stability testing method
Study finds Broadband Acoustic Resonance Dissolution Spectroscopy (BARDS) to be a potentially more time-efficient and cost-effective method for solid dose stability testing.
Pharmacovigilance Risk Assessment Committee (PRAC) meeting highlights, Oct 2021
EMA's drug safety committee (PRAC) assessed risks with COVID-19 vaccines and identified no risk of death with Imbruvica and ACE inhibitors.
Machine vision allows real-time monitoring and control of low concentration APIs
Machine vision-based concentration determination enabled the accurate real-time monitoring and control of continuous powder blending.
Using co-processed excipient reduces PAT measurement errors, finds study
New research shows co-processed excipient is superior to non-co-processed when using near infrared (NIR) process analytical technology (PAT) to monitor direct compression tableting.
IV suramin may be a promising autism treatment, shows Phase II study
PaxMedica's intravenous (IV) suramin known as PAX-101 had mixed results in Phase II study, but shows potential to reduce autism symptoms.
FDA joins Bespoke Gene Therapy Consortium (BGTC) for rare diseases
The consortium also consists of 10 pharmaceutical companies and five organisations to accelerate gene therapies to treat rare diseases.
Serial radiation therapy an effective alternative for kidney cancer
The single-arm study showed that radiation therapy is an effective noninvasive alternative treatment for renal cell carcinoma (RCC).
Stelara® shows promise to treat gut diseases in new analyses
Two new analyses displayed positive data supporting Stelara for the treatment of Crohn's disease and ulcerative colitis.
CHMP recommends COVID-19 vaccine Spikevax booster dose
The European Medicines Agency (EMA)'s human medicines committee (CHMP) concludes that a booster dose of Spikevax can be administered in adults aged 18 or over.
SEC-MS: a “powerful tool” for ADC analysis, find researchers
Research shows size exclusion chromatography (SEC) with mass spectrometry (MS) enables the simple, quick and reliable analysis of antibody-drug conjugates (ADCs).
